Anti-<i>Mycobacterium tuberculosis</i>and Cytotoxicity Activities of Ruthenium(II)/Bipyridine/Diphosphine/Pyrimidine-2-thiolate Complexes: The Role of the Non-Coordinated<i>N</i>-Atom

Lima, Benedicto Augusto Vieira; Corrêa, Rodrigo S.; Graminha, Angélica E.; Kuznetsov, Aleksey E.; Ellena, Javier; Pavan, Fernando Rogério; Leite, Clarice Q. F.; Batista, Alzir A.

doi:10.5935/0103-5053.20150237

Cited by 6 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complexes 1 and 2 are also active, presenting IC 50 values comparable with other ruthenium(II)/phosphine complexes. 11,12,27 The isomer cis-[RuCl 2 (dppb)(dpqQX)] (2) is more active than the trans-[RuCl 2 (dppb)(dpqQX)] (1) one. Probably, due to the lability of the chlorine ligand trans to a phosphorus atom, forming the cationic species [RuCl(L)(dppb)(dpqQX)] + (where L = solvent), such as occur in analogous complexes.…”

Section: Antitumoral Activitymentioning

confidence: 99%

“…Recently, we have synthesized several classes of phosphine ruthenium(II) complexes with N-heterocyclic ligands and we have evaluated their cytotoxicity against tumor cancer cells, in which promising results have been obtained. 11,12 Therefore, as part of our ongoing research to obtain new compounds with potential cytotoxic effects, three neutral complexes were obtained with the general formula [RuCl 2 (P-P)(dpqQX)], where P-P is dppb (1,4-bis(diphenylphosphino)butane) or (PPh 3 ) 2 (triphenylphosphine) and dpqQX = dipyrido[3,2-a:2',3'-c] quinoxaline [2,3-b]quinoxaline, a planar heteroaromatic ligand with high electronic conjugation. Also, an ionic compound ct-[RuCl(CO)(dppb)(dpqQX)]PF 6 was synthesized by exchange of a chorine trans to phosphorus to one carbonyl ligand (Scheme 1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Polypyridyl Ruthenium Complexes: Novel DNA-Intercalating Agents against Human Breast Tumor

Barolli¹,

Corrêa²,

Miranda³

et al. 2017

J. Braz. Chem. Soc.

Self Cite

View full text Add to dashboard Cite

This paper describes a new series of four DNA-intercalating agents with promising anticancer activities, based on ruthenium(II) with the planar ligand dpqQX (dpqQX = dipyrido[3,2-a:2',3'-c] quinoxaline [2,3-b] quinoxaline). The complexes identified as trans-[RuCl(dppb = 1,4-bis(diphenylphosphine)butane and PPh 3 = triphenylphosphine) were characterized by 31 P{ 1 H} nuclear magnetic resonance (NMR) and infrared spectroscopies, cyclic voltammetry, molar conductance measurements, elemental analysis, mass spectrometry and X-ray diffraction analysis for complex ct-[RuCl 2 (PPh 3 ) 2 (dpqQX)]. Their in vitro cytotoxic activities against MDA-MB-213 and MCF-7 breast cancer cells were evaluated and compared with normal L-929 cells. Low drug concentration at which 50% of the cells are viable relative to the control (IC 50 ) values were obtained for all four complexes compared with a reference metallodrug, cisplatin. In addition, DNA affinity studies from titrations, as well as the images obtained by atomic force microscopy (AFM) involving pBR322 plasmid DNA, suggest interactions between the metal complexes and the DNA macromolecule, in which they act as intercalating agents. The intercalation of the complexes with DNA was confirmed by viscosity measurements.

show abstract

Section: Antitumoral Activitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Polypyridyl Ruthenium Complexes: Novel DNA-Intercalating Agents against Human Breast Tumor

Barolli¹,

Corrêa²,

Miranda³

et al. 2017

J. Braz. Chem. Soc.

Self Cite

View full text Add to dashboard Cite

show abstract

“…For biological activities, pyridine compounds are widely used as antibacterial, antifungal, and anticancer agents. [1][2][3] Several studies have been conducted on biological compounds in health-related journals and books. Accordingly, pyridine derivatives cause interactions with high binding capacity by targeting enzymes, proteins, and deoxyribonucleic acid (DNA) that create biological problems.…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Crystallographic Structure, Hirshfeld Surface Analysis, Drug-likeness Properties and Molecular Docking Studies of New Oxime-pyridine Compounds

Topal

2021

ACSi

View full text Add to dashboard Cite

A detailed description of the two new pyridine ligands, (2E,3Z)-3-[2-(3-chloropyridin-2-yl)hydrazinylidene]-N-hydroxybutan-2-imine and 3-chloro-2-{(2Z)-2-[1-(4 nitrophenyl)ethylidene]hydrazinyl}, is reported. The synthesized compounds were characterized by spectroscopic studies, spectral features were performed by TD-DFT calculations. New-generation pyridine ligand of HL2 was also determinate by single-crystal X-ray diffraction and Hirshfeld surface analysis with two-dimensional fingerprint plots was used to analyze intermolecular interactions in crystals. Molecular-docking was performed to investigate the binding areas of chemical compounds, and the results showed the inhibitory activity of the studied HL1 and HL2 against E. coli. The results of the current study revealed the drug-likeness and bioactive properties of the ligands.

show abstract

“…18,19 Preliminary results obtained by our research group for ruthenium(II) complexes containing 2,2'-bipyridine (bipy) and its derivatives, as well as diphosphines as ligands, are very promising as anticancer agents. [20][21][22] These results have encouraged us to explore these kinds of systems, not only because of the good results obtained, but also because it is possible to investigate the relationship between the structural parameter of the complexes and their biological activity. Recently, we have observed that the substitution of chlorido ligands from the cis-[RuCl 2 (dppe) 2 ] (dppe: 1,2-bis(diphenylphosphino)ethane) complex by a propionate ligand, forming the [Ru(η 2 -O 2 CCH 2 CH 3 )(dppe) 2 ]PF 6 complex, increased the cytotoxicity against a series of tumor cells (GM07492A, HepG2, MCF-7, MO59 J, S180), when compared with the starting precursor.…”

Section: Introductionmentioning

confidence: 99%

New Heteroleptic RuII/Diphosphine Complexes with Cytotoxicity against Human Breast and Murine Ascitic Sarcoma 180 Tumor Cells

Lima¹,

Corrêa²,

Graminha³

et al. 2020

J. Braz. Chem. Soc.

Self Cite

View full text Add to dashboard Cite

The preparation, characterization, theoretical calculations and biological application of four Ru II complexes with 2-picolinate (pic), 2,2'-bipyridine (bipy) and P-P as ligands [P-P = 1,1-bis(diphenylphosphino)methane (dppm-1), 1,2-bis(diphenylphosphino)ethane (dppe-2), 1,3-bis(diphenylphosphino)propane (dppp-3) or 1,1'-bis(diphenylphosphino)ferrocene (dppf-4)], is here presented. The complexes 1-4, with general formula [Ru(pic)(P-P)(bipy)]PF 6 , were characterized by elemental analysis and by infrared (IR), UV-Vis, nuclear magnetic resonance (NMR 1 H and 13 P{ 1 H}) spectroscopies, cyclic voltammetry and X-ray crystallography technique. Additionally, preliminary in vitro tests against human breast (MDA-MB-231) and murine ascitic sarcoma 180 (S180) tumor cell lines were carried out, and compared with cisplatin, a reference drug. The drug concentration at which 50% of the cells are viable relative to the control (IC 50) values found for complexes 1, 2, 3 and 4 against MDA-MB-231 tumor cells were around 14.6, 7.6, 3.3 and 0.4 μM, respectively, while against S180 tumor cells these complexes showed IC 50 values of 71.9, 31.3, 11.2 and 3.5 μM, respectively. Therefore, the complexes were more active against MDA-MB-231 than S180.

show abstract

Anti-Mycobacterium tuberculosisand Cytotoxicity Activities of Ruthenium(II)/Bipyridine/Diphosphine/Pyrimidine-2-thiolate Complexes: The Role of the Non-CoordinatedN-Atom

Cited by 6 publications

References 2 publications

Polypyridyl Ruthenium Complexes: Novel DNA-Intercalating Agents against Human Breast Tumor

Polypyridyl Ruthenium Complexes: Novel DNA-Intercalating Agents against Human Breast Tumor

Synthesis, Crystallographic Structure, Hirshfeld Surface Analysis, Drug-likeness Properties and Molecular Docking Studies of New Oxime-pyridine Compounds

New Heteroleptic RuII/Diphosphine Complexes with Cytotoxicity against Human Breast and Murine Ascitic Sarcoma 180 Tumor Cells

Contact Info

Product

Resources

About